Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,237 across all filing types
Latest filing 2025-07-08 Notice of Dividend Amou…
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
General Updates
Notice of Dividend Amount Classification · 95% confidence The document is a communication addressed to stock exchanges and shareholders regarding the tax deduction at source (TDS) on dividends payable for the financial year ending March 31, 2025. It explains the tax provisions under the Income Tax Act, 1961, amendments, and the process shareholders must follow to submit relevant tax documents before a cut-off date. The document references the upcoming 40th Annual General Meeting (AGM) where the dividend will be approved and provides detailed instructions on tax deduction procedures, forms, and exemptions. It does not contain financial statements, earnings data, or management discussion but is an informational notice about dividend tax deduction and related shareholder formalities. It is not a report itself but a communication or announcement to shareholders and regulators about dividend tax deduction procedures. Therefore, it fits best under the category of Notice of Dividend Amount (DIV), as it relates to dividend payment details and tax deduction information for shareholders.
2025-07-08 English
Please find enclosed the certificate received under Regulation 74(5) of SEBI (DP) Regulation 2018 for the quarter ended June 30, 2025.
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2025. It is issued by the Registrar and Share Transfer Agent confirming dematerialisation of securities and related compliance. The document is addressed to stock exchanges and the company secretary, and it is a compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data, nor is it an announcement of voting results, management changes, or capital changes. It is a regulatory compliance certificate related to securities dematerialisation. Given the nature and length (3418 characters), it is not a report publication announcement but a regulatory filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-07-04 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2025. It is issued by the Registrar and Share Transfer Agent confirming dematerialisation of securities and related compliance. The document is addressed to stock exchanges and the company, and it is a compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data. The document length is 3418 characters, which is relatively short and consistent with a regulatory compliance certificate. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and certifications that do not fit other specific categories.
2025-07-04 English
Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Regulatory Filings Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about the receipt of a Show Cause Notice from a tax authority regarding IGST refund claims. The document includes details of the litigation and expected financial implications but does not contain any financial statements or detailed financial analysis. It is a regulatory announcement about a legal proceeding rather than a full legal proceedings report or financial report. Given the nature of the content and the regulatory context, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-07-02 English
Please find attached the intimation regarding the Show Cause Notice issued by the Joint Commissioner of CGST and Central Excise, Mumbai.
Legal Proceedings Report Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about the receipt of a Show Cause Notice from a tax authority regarding a GST refund claim. The document includes details of the litigation and expected financial implications but does not contain any financial statements or detailed financial analysis. The length is 3719 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. There is no indication that this is a full audit report, annual report, or earnings release. The content is focused on legal proceedings and regulatory compliance disclosure. Therefore, the most appropriate classification is Legal Proceedings Report (LTR).
2025-07-02 English
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Gagan Harsh Sharma & PACs
Regulatory Filings
2025-07-01 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.